Cyprotex Ltd - Strategic SWOT Analysis Review

October 2017 | 36 pages | ID: CD9DC381798EN
GlobalData

Abstracts

Cyprotex Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – GlobalData’s summarization of the company’s business strategy.
• SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
• Key manufacturing facilities – A list of key manufacturing facilities of the company.

Highlights

Cyprotex Ltd (Cyprotex), a subsidiary of Evotec AG is a provider of ADME-Tox contract research services. It provides these services to the biotechnology, pharmaceutical, cosmetics/personal care and chemical industries. The company’s core capabilities include high quality mechanistic toxicology, in vitro ADME screening services, and high content toxicology screening services, including proprietary CellCiphr toxicity prediction technology, predictive modelling using QSAR and PBPK techniques, including Cloe PK for in vivo PK prediction, and a range of endocrine and skin, ocular disruption services. Cyprotex partners with various organizations within the cosmetics and personal care industry, biotech and pharmaceutical industry, and the chemical industry. The company's operations are primarily carried out in the UK and the US. Cyprotex is headquartered in Nether Alderley, Cheshire, the UK.

Cyprotex Ltd Key Recent Developments

Jan 26,2017: Cyprotex, an Evotec Company, Expands into New UK Facility at Alderley Park
Nov 29,2016: Cyprotex: Launch of in vitro h-CLAT Service for assessing skin sensitisation
Oct 06,2016: Cyprotex: New DDI-Fusion Combines Chemical Structure with In Vitro Data to Predict Human Drug-Drug Interactions
Sep 26,2016: Cyprotex: Cyprotex appoint new Director of US Operations
Sep 26,2016: Cyprotex appoint new Director of US Operations

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Contents

SECTION 1 - ABOUT THE COMPANY

Cyprotex Ltd - Key Facts
Cyprotex Ltd - Key Employees
Cyprotex Ltd - Key Employee Biographies
Cyprotex Ltd - Major Products and Services
Cyprotex Ltd - History
Cyprotex Ltd - Company Statement
Cyprotex Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Cyprotex Ltd - Business Description
Cyprotex Ltd - SWOT Analysis
SWOT Analysis - Overview
Cyprotex Ltd - Strengths
Cyprotex Ltd - Weaknesses
Cyprotex Ltd - Opportunities
Cyprotex Ltd - Threats
Cyprotex Ltd - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Cyprotex Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Cyprotex Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Cyprotex Ltd, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Nov 29, 2016: Cyprotex: Launch of in vitro h-CLAT Service for assessing skin sensitisation
Oct 06, 2016: Cyprotex: New DDI-Fusion Combines Chemical Structure with In Vitro Data to Predict Human Drug-Drug Interactions
Sep 26, 2016: Cyprotex: Cyprotex appoint new Director of US Operations
Sep 26, 2016: Cyprotex appoint new Director of US Operations
Sep 13, 2016: Cyprotex extends its metabolite identification service to support human clinical samples
Aug 25, 2016: Cyprotex install two AB Sciex TripleTOF 6600 mass spectrometer systems
Aug 02, 2016: Cyprotex: Interim Results 2016
Jul 07, 2016: Cyprotex Announces Launch of New Advanced 3D Cardiotoxicity Model
Jun 23, 2016: Cyprotex Launch New Endocrine Disruption Service
Jun 09, 2016: Cyprotex Purchase New IntelliCyt iQue Screener for Expansion of Cell-Based Services

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Cyprotex Ltd, Key Facts
Cyprotex Ltd, Key Employees
Cyprotex Ltd, Key Employee Biographies
Cyprotex Ltd, Major Products and Services
Cyprotex Ltd, History
Cyprotex Ltd, Subsidiaries
Cyprotex Ltd, Key Competitors
Cyprotex Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Cyprotex Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Cyprotex Ltd, Recent Deals Summary

List Of Figures

LIST OF FIGURES

Cyprotex Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Cyprotex Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

Synairgen Plc
Stem Cell Theranostics Inc
Silence Therapeutics Plc
Scancell Holdings Plc
Proteome Sciences Plc
Omega Diagnostics Group Plc
IXICO Plc
GW Pharmaceuticals Plc